Literature DB >> 1565242

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group.

D E Goodkin1, D Cookfair, K Wende, D Bourdette, P Pullicino, B Scherokman, R Whitham.   

Abstract

We determined inter- and intrarater Kurtzke Expanded Disability Status Scale (EDSS) scoring agreement for four trained examining physicians who evaluated 10 clinically stable multiple sclerosis patients. These patients had previously been determined to have EDSS scores of 1.0 to 3.5 and were scheduled to participate in a funded clinical trial of intramuscular recombinant interferon-beta. Intrarater reliability was greater than interrater reliability for scoring the EDSS and all of its component functional systems scores (FSS). Specifically, individual examiners were able to reproduce three serial examination scores on the same patient on the same day (intrarater agreement) within 1.0 EDSS or 2.0 individual FSS points. Reproducible scoring across examiners (interrater agreement), however, could only be accomplished within 1.5 EDSS or 3.0 individual FSS points. Additionally, the interrater scoring variability in our patients is greater than that previously reported for patients with higher EDSS scores. We conclude that clinical trials that employ the EDSS as an outcome measure of treatment efficacy should include inter- and intrarater agreement data for all examining physicians. Most importantly, studies using a single examining physician to evaluate individual patients throughout the course of a clinical trial will require less change in the EDSS to reliably measure disease activity than will studies using more than one examining physician to evaluate individual patients throughout the trial.

Entities:  

Mesh:

Year:  1992        PMID: 1565242     DOI: 10.1212/wnl.42.4.859

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

Review 1.  Interferon in relapsing-remitting multiple sclerosis.

Authors:  G P Rice; B Incorvaia; L Munari; G Ebers; C Polman; R D'Amico; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

Review 3.  When drug companies select what they want to publish patients are denied relevant therapeutic information.

Authors:  Graziella Filippini; Lorenzo Moja; Alessandro Liberati; Gian Franco Gensini; Roberto Gusinu; Andrea A Conti
Journal:  Intern Emerg Med       Date:  2008-09       Impact factor: 3.397

4.  Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis.

Authors:  Jiwon Oh; Min Chen; Kateryna Cybulsky; Suradech Suthiphosuwan; Estelle Seyman; Blake Dewey; Marie Diener-West; Peter van Zijl; Jerry Prince; Daniel S Reich; Peter A Calabresi
Journal:  Mult Scler       Date:  2020-06-01       Impact factor: 6.312

Review 5.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

Review 6.  More immunotherapy for multiple sclerosis.

Authors:  R A Hughes; B Sharrack
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

7.  Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease.

Authors:  S J Pittock; R L McClelland; S J Achenbach; F Konig; A Bitsch; W Brück; H Lassmann; J E Parisi; B W Scheithauer; M Rodriguez; B G Weinshenker; C F Lucchinetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

8.  Body-worn sensors capture variability, but not decline, of gait and balance measures in multiple sclerosis over 18 months.

Authors:  Rebecca I Spain; Martina Mancini; Fay B Horak; Dennis Bourdette
Journal:  Gait Posture       Date:  2013-12-21       Impact factor: 2.840

9.  Disease-related determinants of quality of life 10 years after clinically isolated syndrome.

Authors:  R Philip Kinkel; Genevieve Laforet; Xiaojun You
Journal:  Int J MS Care       Date:  2015 Jan-Feb

10.  The treatment of chronic progressive multiple sclerosis with cladribine.

Authors:  E Beutler; J C Sipe; J S Romine; J A Koziol; R McMillan; J Zyroff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.